ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR

(2018) Imran Shair Mohammad et al.   BIOMEDICINE & PHARMACOTHERAPY

Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents

(2017) Giovanni Luca Beretta et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression

(2017) Sheng-Ming Wu et al.   INTERNATIONAL JOURNAL OF CANCER

The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer

(2016) Hongjing Zang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10

(2016) Kai Wu et al.   CANCER LETTERS

Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance

(2015) Jezrael L. Revalde et al.   BIOCHEMICAL PHARMACOLOGY

MicroRNA-9 induces defective trafficking of Nav1.1 and Nav1.2 by targeting Navβ2 protein coding region in rat with chronic brain hypoperfusion

(2015) Li-Hua Sun et al.   Molecular Neurodegeneration

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells

(2015) Yinsong Zhu et al.   Scientific Reports

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

(2013) J-Y Douillard et al.   BRITISH JOURNAL OF CANCER

EGFR signaling and autophagy dependence for growth, survival, and therapy resistance

(2013) Barry Jutten et al.   CELL CYCLE

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

(2013) David R. Gandara et al.   Clinical Lung Cancer

P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives

(2013) Ziyad Binkhathlan et al.   CURRENT CANCER DRUG TARGETS

Age is a prognostic factor affecting survival in lung cancer patients

(2013) FARUK TAS et al.   Oncology Letters

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance

(2012) Csilla Hegedüs et al.   BIOCHEMICAL PHARMACOLOGY

The controversial role of ABC transporters in clinical oncology

(2011) Akina Tamaki et al.   Essays in Biochemistry

Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs

(2011) Florie Borel et al.   HEPATOLOGY

ABCG2 is a High-Capacity Urate Transporter and its Genetic Impairment Increases Serum Uric Acid Levels in Humans

(2011) Akiyoshi Nakayama et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

(2011) Yun-Ju Chen et al.   PLoS One

The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)

(2010) Pavitra Kannan et al.   ACS Chemical Neuroscience

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

(2010) Eric B. Haura et al.   Journal of Thoracic Oncology

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance

(2009) Ye-Hong Kuang et al.   BIOCHEMICAL PHARMACOLOGY

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

(2009) Amalia Azzariti et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance

(2008) Ying Zhou et al.   BIOCHEMICAL PHARMACOLOGY